Day: October 13, 2022

Sever, Belgin; Akalin Ciftci, Guelsen; Altintop, Mehlika Dilek published the artcile< A new series of benzoxazole-based SIRT1 modulators for targeted therapy of non-small-cell lung cancer>, Computed Properties of 13451-78-0, the main research area is NSCLC anticancer SIRT1 modulator mol docking apoptosis ADME; SIRT1; apoptosis; benzimidazole; benzoxazole; molecular docking; non-small-cell lung cancer.

In an attempt to identify potential anticancer agents for non-small-cell lung cancer (NSCLC) targeting sirtuin 1 (SIRT1), the synthesis of a new series of benzoxazoles (3a – i) was carried out through a facile and versatile synthetic route. The compounds were evaluated for their cytotoxic effects on A549 human lung adenocarcinoma and NIH/3T3 mouse embryonic fibroblast cells using the MTT assay. 2-[(5-Nitro-1H-benzimidazol-2-yl)thio]-N-(2-methylbenzoxazol-5-yl)acetamide (3e) and 2-[(5-chloro-1H-benzimidazol-2-yl)thio]-N-(2-methylbenzoxazol-5-yl)acetamide (3g) were the most potent and selective anticancer agents in this series against the A549 cell line, with IC50 values of 46.66 ± 11.54 and 55.00 ± 5.00μM, resp. The flow cytometry-based apoptosis detection assay was performed to determine their effects on apoptosis in A549 cells. Both compounds induced apoptosis in a dose-dependent manner. The effects of compounds 3e and 3g on SIRT1 activity were determined On the basis of in vitro studies, it was observed that compound 3g caused a significant decrease in SIRT1 levels in a dose-dependent manner, whereas compound 3e increased the SIRT1 levels. According to mol. docking studies, the substantial alteration in the type of action could be attributed to the difference between the interactions of compounds 3e and 3g with the same residues in the active site of SIRT1 (PDB code: 4IG9). On the basis of in silico ADME (absorption, distribution, metabolism, and excretion) studies, these compounds are predicted to possess favorable ADME profiles. According to the in vitro and in silico studies, compounds 3e and 3g, small-mol. SIRT1 modulators, were identified as potential orally bioavailable anticancer agents for the targeted therapy of NSCLC.

Archiv der Pharmazie (Weinheim, Germany) published new progress about Antitumor agents. 13451-78-0 belongs to class benzoxazole, and the molecular formula is C7H4FNOS, Computed Properties of 13451-78-0.

Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem

Varun, Begur Vasanthkumar; Gadde, Karthik; Prabhu, Kandikere Ramaiah published the artcile< Sulfenylation of β-Diketones Using C-H Functionalization Strategy>, SDS of cas: 13451-78-0, the main research area is bezoxazolethione diketone sulfenylation cross dehydrogenative coupling; bezoxazolyl sulfenylated diketone preparation.

Sulfenylation of β-diketones is challenging as β-diketones undergo deacylation after sulfenylation in the reaction medium. The sulfenylation of β-diketones without deacylation under metal-free conditions at ambient temperature via a cross dehydrogenative coupling (CDC) strategy is reported. The resultant products can be further manipulated to form α,α-disubstituted β-diketones and pyrazoles.

Organic Letters published new progress about Diketones, 1,3-diketones Role: RCT (Reactant), SPN (Synthetic Preparation), RACT (Reactant or Reagent), PREP (Preparation). 13451-78-0 belongs to class benzoxazole, and the molecular formula is C7H4FNOS, SDS of cas: 13451-78-0.

Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem

Yamazaki, Yukiyoshi; Abe, Kazutoyo; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Araki, Takaaki; Oda, Soichi; Inoue, Keisuke; Shibuya, Kimiyuki; Staels, Bart; Fruchart, Jean-Charles published the artcile< Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists>, Reference of 13451-78-0, the main research area is aryloxyalkyl benzoxazole substituted aminoalkyl aryloxyalkanoic acid preparation PPAR agonist; structure aminoalkyl aryloxyalkanoic acid activity selectivity PPAR alpha agonist; hypolipemic activity PPAR binding selectivity aminoalkyl aryloxyalkanoic acid.

Aryloxyalkanoic acids substituted with aryloxyalkyl and benzoxazole-substituted aminoalkyl groups such as I are prepared as human peroxisome proliferator-activated receptor α (PPAR-α) agonists for decreasing lipid levels; the binding of the compounds to PPAR-α, PPAR-δ, and PPA-γ and the decreases in liver weight and triglyceride levels in rats upon administration of the sodium salts of three of the compounds are determined The racemate of I is prepared and resolved by HPLC to provide I and its enantiomer; I inhibits PPAR-α with an EC50 value of 1 nM and approx. 1000-fold selectivity over PPAR-δ and PPAR-γ, while the sodium salt of I decreases triglyceride concentrations in rats by approx. 49%.

Bioorganic & Medicinal Chemistry Letters published new progress about Apolipoprotein A-I Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 13451-78-0 belongs to class benzoxazole, and the molecular formula is C7H4FNOS, Reference of 13451-78-0.

Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem

Mitra, Raja; Samuelson, Ashoka G. published the artcile< Substitution-Modulated Anticancer Activity of Half-Sandwich Ruthenium(II) Complexes with Heterocyclic Ancillary Ligands>, Application In Synthesis of 13451-78-0, the main research area is crystal mol structure cymeneruthenium mercaptobenzoxazole mercaptobenzothiazole mercaptobenzimidazole preparation anticancer.

Ten new organometallic half-sandwich Ru complexes with heterocyclic ligands were synthesized. The substituents on the ancillary heterocyclic ligands were varied to understand the effect of substitution on anticancer activity. The crystallog. characterization of five complexes confirms that they adopt three-legged piano-stool structures and are stabilized by intramol. H bonding. The two complexes with chloro- and bromo-substituted mercaptobenzothiazole ligands exhibit halogen bonding in the solid state. In aqueous media, the complexes form dinuclear Ru species. The complex with the noncytotoxic heterocycle, 6-fluoro-2-mercaptobenzothiazole, and the complex with the unsubstituted 2-mercaptobenzothiazole are the most active against A2780 and KB cell lines. The substitution of the H atoms on the ancillary ligand with Cl or Br atoms decreases the anticancer activity. With the exception of the F-substituted mercaptobenzoxazole ligand, the complexes with mercaptobenzoxazole ligands are inactive against all of the tested cell lines. Ru complexes with mercaptonaphthimidazole and mercaptobenzimidazole do not show any anticancer activity. The active complexes show a biphasic melting curve when incubated with calf thymus (CT) DNA. These complexes only inhibit thioredoxin reductase (TrxR) enzyme activity to a small extent. The substitution of H atoms with F atoms in the aromatic heterocyclic ligands on the organometallic half-sandwich Ru complexes has the most beneficial effect on their anticancer activity.

European Journal of Inorganic Chemistry published new progress about Antitumor agents. 13451-78-0 belongs to class benzoxazole, and the molecular formula is C7H4FNOS, Application In Synthesis of 13451-78-0.

Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem